Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2018

01-12-2018 | Hospital- based Dermatology (D Kroshinsky, Section Editor)

Pediatric Inpatient Dermatology: New Insights on Severe Eruptions and Cutaneous Adverse Reactions

Authors: Priya Cherukuri, Diana W. Bartenstein, Elena B. Hawryluk

Published in: Current Dermatology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

This manuscript reviews important advances in our understanding of severe eruptions and cutaneous adverse reactions in children.

Recent Findings

The latest research provides significant insights regarding severe cutaneous eruptions including coxsackievirus eruptions, mycoplasma-induced rash and mucositis, urticaria multiforme, erythema multiforme, and severe cutaneous adverse reactions. Recent literature expands our understanding of the incidence and cost, pathophysiology, and management considerations for pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Summary

Pediatric inpatient cutaneous eruptions, from infectious and inflammatory to adverse reactions are very burdensome diseases. It is important to recognize salient features to initiate appropriate workup and management, particularly for patients with severe cutaneous adverse reactions for which early recognition of complications of disease and consultation with colleagues may minimize sequelae.
Literature
1.
Hubiche T, Schuffenecker I, Boralevi F, Léauté-Labrèze C, Bornebusch L, Chiaverini C, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J. 2014;33(4):e92–8.CrossRef
2.
•• Mathes EF, Oza V, Frieden IJ, Cordoro KM, Yagi S, Howard R, et al. “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak. Pediatrics. 2013;132(1):e149–57 A retrospective case series describing atypical presentations of HFMD associated with a North American CVA6 outbreak.CrossRef
3.
Nassef C, Ziemer C, Morrell DS. Hand-foot-and-mouth disease: a new look at a classic viral rash. Curr Opin Pediatr. 2015;27(4):486–91.CrossRef
4.
Neri I, Dondi A, Wollenberg A, Ricci L, Ricci G, Piccirilli G, et al. Atypical forms of hand, foot, and mouth disease: a prospective study of 47 Italian children. Pediatr Dermatol. 2016;33(4):429–37.CrossRef
5.
Apalla Z, Sotiriou E, Pikou O, Lefaki I, Lallas A, Lazaridou E, et al. Onychomadesis after hand-foot-and-mouth disease outbreak in northern Greece: case series and brief review of the literature. Int J Dermatol. 2015;54(9):1039–44.CrossRef
6.
Böer-Auer A, Metze D. Histopathology of hand-foot-mouth disease in adults and criteria for differentiation from erythema multiforme. Am J Dermatopathol. 2018;11.
7.
•• Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239–45 Classification of MIRM as a clinical entity distinct from other mucocutaneous eruptions, with diagnostic and morphological criteria described.CrossRef
8.
Santos RP, Silva M, Vieira AP, Brito C. Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity. BMJ Case Rep. 2017;22:2017.
9.
Curtiss P, Melnick L, Sicco KL, Liebman TN. Mycoplasma pneumoniae, more than a lung disease. Dermatol Online J. 2018;24(6).
10.
Norton SA. Diagnosing Mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room. J Am Acad Dermatol. 2015;73(2):e67.CrossRef
11.
Mayor-Ibarguren A, Feito-Rodriguez M, González-Ramos J, Del Rosal-Rabes T, González-Sainz FJ, Sánchez-Orta A, et al. Mucositis secondary to Chlamydia pneumoniae infection: expanding the Mycoplasma pneumoniae-induced rash and mucositis concept. Pediatr Dermatol. 2017;34(4):465–72.CrossRef
12.
Samorano LP, Fernandez VV, Valente NYS, Arnone M, Nico MMS, Rivitti-Machado MCM, et al. Urticaria multiforme: two cases with histopathological findings. Allergol Int Off J Jpn Soc Allergol. 2017;66(1):154–5.CrossRef
13.
Sempau L, Martín-Sáez E, Gutiérrez-Rodríguez C, Gutiérrez-Ortega MC. Urticaria multiforme: a report of 5 cases and a review of the literature. Actas Dermosifiliogr. 2016;107(1):e1–5.CrossRef
14.
Kotlyar S. Images In Clinical Medicine. Urticaria multiforme. N Engl J Med. 2016;375(5):470.CrossRef
15.
•• Ercan N, Samorano LP, Fernandez VV, Valente NYS, Arnone M, Nico MMS, et al. Corticosteroid use in urticaria multiforme cases. Allergol Int. 2017;66(3):488–9 A response detailing the lack of clinical efficacy of corticosteroid treatment for UM.CrossRef
16.
Siedner-Weintraub Y, Gross I, David A, Reif S, Molho-Pessach V. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol. 2017;97(4):489–92.CrossRef
17.
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018;54(1):177–84.CrossRef
18.
Read J, Keijzers GB. Pediatric erythema multiforme in the emergency department: more than “just a rash.”. Pediatr Emerg Care. 2017;33(5):320–4.CrossRef
19.
Heinze A, Tollefson M, Holland KE, Chiu YE. Characteristics of pediatric recurrent erythema multiforme. Pediatr Dermatol. 2018;35(1):97–103.CrossRef
20.
Coates SJ, Briggs B, Cordoro KM. Tularemia-induced erythema multiforme minor in an 11-year-old girl. Pediatr Dermatol. 2018;35(4):478–81.CrossRef
21.
Chen T, Levitt J, Geller L. Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J. 2017;23(1).
22.
Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811–817.e4.CrossRef
23.
Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS. Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol. 2018;189:17–28.CrossRef
24.
Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34(6):1235–44.CrossRef
25.
Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol. 2018;35(2):182–7.CrossRef
26.
Manolio Teri A, Hutter Carolyn M, Mark A, Ricardo C, Davis Robert L, Denny Joshua C, et al. Research directions in genetic predispositions to Stevens–Johnson syndrome/toxic epidermal necrolysis. Clin Pharmacol Ther. 2018;103(3):390–4.CrossRef
27.
White ML, Chodosh J, Jang J, Dohlman C. Incidence of Stevens-Johnson syndrome and chemical burns to the eye. Cornea. 2015;34(12):1527–33.CrossRef
28.
Conner CD, McKenzie E, Owen CE, Callen JP. The use of cyclosporine for Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum at the University of Louisville: a case series and literature review. Dermatol Online J. 2018;24(1).
29.
Sorrell J, Anthony L, Rademaker A, Belknap SM, Callahan S, West DP, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol. 2017;34(4):433–7.CrossRef
30.
Beck A, Quirke KP, Gamelli RL, Mosier MJ. Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough. J Burn Care Res Off Publ Am Burn Assoc. 2015;36(1):167–77.CrossRef
31.
Ferrándiz-Pulido C, García-Fernández D, Domínguez-Sampedro P, García-Patos V. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a University Hospital. J Eur Acad Dermatol Venereol. 2011;25(10):1153–9.CrossRef
32.
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–97.CrossRef
33.
•• Wang C-W, Yang L-Y, Chen C-B, Ho H-C, Hung S-I, Yang C-H, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–96 A randomized control trial studying the efficacy of etanercept in adult SJS/TEN found improved clinical outcomes with etanercept compared to treatment with corticosteroids, an improvement in SCORTEN-predicted mortality, as well as reductions in TNF-α and granulysin secretions in patient plasma and blister fluids.CrossRef
34.
Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–76.CrossRef
35.
Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J. 2018;24(1).
36.
• Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76(1):106–13 A retrospective cohort study of 44 adult SJS/TEN patients evaluating efficacy of cyclosporine treatment found improvements in SCORTEN-predicted mortality with use of cyclosporine.CrossRef
37.
St. John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34(5):540–6.CrossRef
38.
Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo L, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care. 2017;42:65–8.CrossRef
39.
Bellodi-Schmidt F, Shah KN. Beyond psoriasis: novel uses for biologic response modifiers in pediatric dermatology. Pediatr Dermatol. 2016;33(1):18–27.CrossRef
40.
Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis. 2018;101(1):E15–21.PubMed
41.
Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by Etanercept. J Cutan Med Surg. 2018;1:1203475418758989.
42.
Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol. 2011;38(3):236–45.CrossRef
43.
Hung P-C, Wang H-S, Hsia S-H, Wong AM-C. Plasmapheresis as adjuvant therapy in Stevens–Johnson syndrome and hepatic encephalopathy. Brain and Development. 2014;36(4):356–8.CrossRef
44.
Hinc-Kasprzyk J, Polak-Krzemińska A, Głowacka M, Ożóg-Zabolska I. The use of plasmapheresis in a 4-year-old boy with toxic epidermal necrosis. Anaesthesiol Intensive Ther. 2015;47(3):210–3.CrossRef
45.
• Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924–35 A review evaluating long-term complications of SJS/TEN that highlights the multi-organ involvement of the disease, with respect to chronic, delayed sequelae that occur in survivors. In particular, this review describes pulmonary, urogenital, gastrointestinal, and psychological sequelae, and provides an assessment protocol to be used during follow-up in the chronic stage of disease.CrossRef
46.
Catt CJ, Hamilton GM, Fish J, Mireskandari K, Ali A. Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol. 2016;166:68–75.CrossRef
47.
Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160(2):228–237.e2.CrossRef
48.
Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis - a comprehensive review and guide to therapy. II Ophthalmic Disease Ocul Surf. 2016;14(2):168–88.CrossRef
49.
Rathi VM, Taneja M, Dumpati S, Mandathara PS, Sangwan VS. Role of scleral contact lenses in management of coexisting keratoconus and Stevens-Johnson Syndrome. Cornea. 2017;36(10):1267–9.PubMed
50.
Sharma N, Thenarasun SA, Kaur M, Pushker N, Khanna N, Agarwal T, et al. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome: a randomized control trial. Ophthalmology. 2016;123(3):484–91.CrossRef
51.
Ahmad MS, Frank GS, Hink EM, Palestine AG, Gregory DG, McCourt EA. Amniotic membrane transplants in the pediatric population. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2017;21(3):215–8.CrossRef
52.
Yoon HJ, Kim MK, Seo KY, Ueta M, Yoon KC. Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens–Johnson syndrome. Int Ophthalmol. 2017;18:1–8.
53.
Chang J-H, Garg NK, Lunde E, Han K-Y, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57(5):415–29.CrossRef
54.
Kim RY, Chung SK, Kim MS, Ra H. Effects of combined photodynamic therapy and topical bevacizumab treatment on corneal neovascularization in rabbits. Cornea. 2016;35(12):1615–20.CrossRef
55.
Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998;91(2):283–7.CrossRef
56.
Saeed H, Mantagos IS, Chodosh J. Complications of Stevens–Johnson syndrome beyond the eye and skin. Burns. 2016;42(1):20–7.CrossRef
57.
Van Batavia JP, Chu DI, Long CJ, Jen M, Canning DA, Weiss DA. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017;13(5):490.e1–7.CrossRef
58.
Petukhova TA, Maverakis E, Ho B, Sharon VR. Urogynecologic complications in Stevens-Johnson syndrome and toxic epidermal necrolysis: presentation of a case and recommendations for management. JAAD Case Rep. 2016;2(3):202–5.CrossRef
59.
Koh MJ-A, Tay Y-K. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol. 2010;62(1):54–60.CrossRef
60.
Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Drug Saf. 2002;25(13):965–72.CrossRef
Metadata
Title
Pediatric Inpatient Dermatology: New Insights on Severe Eruptions and Cutaneous Adverse Reactions
Authors
Priya Cherukuri
Diana W. Bartenstein
Elena B. Hawryluk
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 4/2018
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-018-0242-9

Other articles of this Issue 4/2018

Current Dermatology Reports 4/2018 Go to the issue

Wound Care and Healing (H Lev-Tov, Section Editor)

Wound Healing with Botanicals: a Review and Future Perspectives

Immunology (D Lee, Section Editor)

Advances in Immune Pathways and Pathogenesis of Atopic Dermatitis

Immunology (D Lee, Section Editor)

Updates on Immunotherapy for the Treatment of Skin Cancer

IImmunology (D Lee, Section Editor)

Epidemiology and Immunopathogenesis of Psoriasis and Its Comorbidities

Atopic Dermatitis (C Vestergaard, Section Editor)

The Skin Microbiome in Atopic Dermatitis—a Potential Treatment Target?

Invited Commentary

Complementary and Alternative Methods for Treatment of Acne Vulgaris: a Systematic Review